Cspc Innovation Pharmaceutical300765.SZValuation Analysis

As of Oct 19, 2026, Cspc Innovation Pharmaceutical (300765.SZ) trades at a P/E of 61.00x, P/B of 15.70x, P/S of 9.56x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 87th percentile over the trailing 10Y window (vs. 55th percentile over 3Y); P/B sits at the 85th percentile over the trailing 10Y window (vs. 64th percentile over 3Y); P/S sits at the 60th percentile over the trailing 10Y window (vs. 5th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 67th percentile within its industry and the 66th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B long-window percentiles differ by only 2.4 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Cspc Innovation Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.